CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models
Disease Models & Mechanisms · 01.08.2024 · 17 (8)
DOI: 10.1242/dmm.050398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 09.09.2024. Verfasst von Nadia Alissa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA. Hauptthemen laut MEDLINE: Chemokine CCL2, Signal Transduction, Muscle, Skeletal, Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Despite advancements in treatment, approximately 25% of patients with breast cancer experience long-term skeletal muscle wasting (SMW), which limits mobility, reduces drug tolerance and adversely impacts survival. By understanding the underlying molecular mechanisms of SMW, we may be able to develop new strategies to alleviate this condition and improve the lives of patients with breast cancer. Chemokines are small soluble factors that regulate homing of immune cells to tissues during inflammation. In breast cancers, overexpression of C-C chemokine ligand 2 (CCL2) correlates with unfavorable prognosis. Elevated levels of CCL2 in peripheral blood indicate possible systemic effects of this chemokine in patients with breast cancer. Here, we investigated the role of CCL2 signaling on SMW in tumor and non-tumor contexts. In vitro, increasing concentrations of CCL2 inhibited myoblast and myotube function through C-C chemokine receptor 2 (CCR2)-dependent mechanisms involving JNK, SMAD3 and AMPK signaling. In healthy mice, delivery of recombinant CCL2 protein promoted SMW in a dose-dependent manner. In vivo knockdown of breast tumor-derived CCL2 partially protected against SMW. Overall, chronic, upregulated CCL2–CCR2 signaling positively regulates SMW, with implications for therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Cell Biology and Physiology and Internal Medicine-Division of Endocrinology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
- Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
- University of Kansas Cancer Center, Kansas City, KS 66160, USA.
ORCID-Profile: Nikki Cheng
Förderung
- NCI NIH HHS
- NIH HHS
- NCRR NIH HHS
- University of Kansas
- NIGMS NIH HHS
- Self Fellow Foundation
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Alissa, N., Fang, W. B., Medrano, M., Bergeron, N., Kozai, Y., Hu, Q., Redding, C., Thyfault, J., Hamilton-Reeves, J., Berkland, C., & Cheng, N. (2024). CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models. Disease Models & Mechanisms, 17(8). https://doi.org/10.1242/dmm.050398
Vancouver
Alissa N, Fang WB, Medrano M, Bergeron N, Kozai Y, Hu Q, et al. CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models. Disease Models & Mechanisms. 2024;17(8). doi:10.1242/dmm.050398
BibTeX
@article{Alissa2024,
author = {Alissa, Nadia and Fang, Wei Bin and Medrano, Marcela and Bergeron, Nick and Kozai, Yuuka and Hu, Qingting and Redding, Chloe and Thyfault, John and Hamilton-Reeves, Jill and Berkland, Cory and Cheng, Nikki},
title = {CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models},
journal = {Disease Models & Mechanisms},
year = {2024},
volume = {17},
number = {8},
doi = {10.1242/dmm.050398}
}
EUVIMED